Translate this page into:
Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients
Reprint requests: Dr Girija Ramaswamy, Professor & Head, Department of Biochemistry, Kidwai Memorial Institute of Oncology, Dr M.H. Marigowda Road, Bangalore 560029, India e-mail: trivenibhat19@yahoo.com
-
Received: ,
Abstract
Background & objectives:
In breast cancer, the HER-2/neu gene is amplified in 20-30 per cent of cases. The mechanism by which the amplification/overexpression occurs is not known. Elevated serum HER-2/neu levels have been shown to be associated with a poor clinical prognosis and decreased survival in early stage breast cancer patients, and thus might help in management of the disease. The present study was therefore to estimate the serum HER-2/neu levels in breast cancer patients and associate with other prognostic factors.
Methods:
Serum HER-2/neu levels were studied in 207 patients with cancer breast, 15 benign breast diseases (BBD) and 175 age-matched healthy controls. Patients' age, menopausal status, node and hormone receptor status were compared with serum HER-2/neu levels.
Results:
Serum HER-2/neu overexpression was associated with age, disease stage and positive nodal status but not with menopausal status. Serum HER-2/neu levels were negatively related with hormone receptor positivity.
Interpretation & conclusion:
HER-2/neu serum test could be done more frequently in women with breast cancer irrespective of the hormone receptor status, to suggest modifications in systemic adjuvant therapy, including possibly the use of Herceptin.
